- Treating HIPAA-safe marketing as a tax produces minimum effort; treating it as a moat produces durable advantage.
- The moat has three layers: first-party data you own, server-side measurement competitors cannot shortcut, and patient trust from not surveilling people.
- These advantages compound — data improves models, reputation lowers acquisition cost, and process maturity reduces rework.
- Skipping compliance is not free: enforcement risk, forced rework, and BAA gaps are deferred costs that come due at the worst time.
Say “HIPAA-compliant marketing” in a growth meeting and watch the energy leave the room. It sounds like the department of no — the reason you cannot use the pixel, the retargeting, the data everyone else seems to use freely. But the brands that have lived inside the constraint for a few years tend to describe it differently. Not as a cage. As a moat.
The reframe
A constraint and a moat can be the same wall, viewed from opposite sides. The pixel you cannot use is also the surveillance your patients do not have to tolerate. The data you cannot borrow from an ad platform is the data you are forced to collect and own yourself. The shortcut you are denied is the shortcut your competitor is also denied — unless they are willing to take a risk that gets more expensive every quarter.
Reframed that way, compliance-first marketing is not the cost of doing business in healthcare. It is the structure of an advantage, if you build for it deliberately rather than grudgingly.
Three layers of moat
Data you own. Forced off third-party tracking, the compliant brand builds first-party data infrastructure — consented, controlled, and portable across whatever the ad platforms do next. That asset appreciates while rivals' borrowed signal degrades.
Measurement competitors cannot shortcut. Server-side conversions, modeled attribution, and controlled experiments take real engineering to stand up. A rival cannot replicate your measurement by pasting a snippet; they have to build the same system, which most will not.
Trust you earn by restraint. Patients increasingly notice when a health brand follows them around the internet; an AMA survey found nearly three in four patients worried about the privacy of their personal health data. Not doing it is itself a brand signal — and in a category built on confidentiality, the absence of creepiness is a feature people feel even if they cannot name it.
Why it compounds
A moat is only a moat if it widens. These do. First-party data makes your targeting and your modeled attribution better the longer you collect it, which lowers acquisition cost, which funds more collection. Reputation for handling patient data well reduces friction at the point of conversion, which improves the very metrics you are optimizing. And process maturity — knowing how to ship marketing that is audit-ready by default — means you move faster over time, not slower, because you are not re-litigating compliance on every campaign.
The brand that treated compliance as a tax pays the same tax every year. The one that treated it as infrastructure stops paying and starts collecting.
The cost of skipping it
The case for the moat is also a warning about the alternative, because non-compliance is never actually free. It is deferred cost. Enforcement risk that crystallizes at the worst possible moment — the FTC’s 2023 orders against GoodRx and BetterHelp, which barred both from sharing health data for advertising, are the template, not the exception. Rework when a borrowed measurement approach is ruled offside and the whole stack has to be rebuilt under deadline. Business-associate-agreement gaps that surface in diligence and shave a turn off a valuation. The brand that skipped the work did not avoid the cost; it scheduled it for later, with interest.
The 1ness Take
The most expensive way to do healthcare marketing is to treat compliance as something to minimize. The minimum-effort posture produces a fragile stack, a nervous legal team, and a deferred bill. The opposite posture — build the owned data, the defensible measurement, the trust — produces an asset that competitors cannot copy with a tag and cannot shortcut with budget.
The wall is there either way. The only choice is whether you are standing behind it or in front of it.
Sources
- FTC enforcement action against GoodRx (Feb 2023) and final order against BetterHelp (July 2023).
- HHS OCR guidance on online tracking technologies (2022; partly vacated June 2024).
- American Medical Association patient data-privacy survey — ~75% of patients concerned about health-data privacy.
